You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 8,790,882

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,790,882

Title:	Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
Abstract:	The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
Inventor(s):	Albitar; Maher (Sugar Land, TX), Keating; Michael J. (Houston, TX), Manshouri; Taghi (Houston, TX)
Assignee:	Board of Regents, The University of Texas System (Austin, TX)
Application Number:	13/934,940
Patent Claims:	1. A method of monitoring the progress of therapy in patient being treated with a therapeutic anti-CD20 antibody, the method comprising testing a sample from the patient to measure the level of circulating cell-free CD20, circulating cell-free anti-CD20 or circulating cell-free CD20/anti-CD20 complexes. 2. The method of claim 1, wherein the sample is selected from the group consisting of serum, cell lysate and plasma. 3. The method of claim 1, wherein the patient is being treated with Rituximab. 4. The method of claim 1, wherein the sample is tested to measure the level of circulating cell-free CD20. 5. The method of claim 1, wherein the sample is tested to measure the level of circulating cell-free anti-CD20. 6. The method of claim 1, wherein the sample is tested to measure the level of circulating cell-free CD20/anti-CD20 complexes.

Details for Patent 8,790,882

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2021-09-20
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2021-09-20
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2021-09-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.